Orexin-2 Receptor Data Reinforces a Positive Outlook for Centessa (CNTA)

Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the 17 biotechnology stocks with more than 50% upside. On January 29, Danielle Brill from Truist Financial raised her price target on Centessa Pharmaceuticals (NASDAQ:CNTA) from $33 to $38 and assigned a Buy rating to the stock. Her rating came after Truist Financial updated its projections following a thorough reassessment of the current data regarding the orexin-2 receptor agonist class. Zoetis (ZTS) Hits New 52-Week Low on Dismal Outlook M. A. Arkhipov ...